Novo Nordisk's (NVO) new type-2 diabetes drug Victoza is rapidly gaining market share in the all-important U.S. market. The Danish drug maker's early commercial success with its subcutaneous "GLP-1" ...

Victoza (liraglutide) is a prescription drug used to help manage type 2 diabetes and reduce the risk of certain diabetes-related heart problems. Victoza is given as a daily injection under the skin.

Results from Novo Nordisk's cardiovascular outcomes study with their diabetes drug Victoza were just released. A very positive 15% reduction in primary composite outcome and 22% reduction in cardiac ...

Ozempic (semaglutide) and Victoza (liraglutide) are prescription drugs used to treat type 2 diabetes and reduce the risk of cardiovascular problems. Both drugs come as an injection. Ozempic is not ...

PARSIPPANY, N.J. - Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), today announced the release of an authorized generic version of Victoza® ...

Novo Nordisk ( NVO) recently announced top-line data on Victoza (liraglutide) from a double-blind phase IIIa study which was conducted to evaluate the potential of Victoza to induce and maintain ...

In mid-April this year, Novo Nordisk obtained the State Food and Drug Administration (SFDA) approval for Victoza (liraglutide recombinant), an injectable treatment for type II diabetes; it plans to ...